Jagsonpal Pharmaceuticals Limited (BOM: 507789)
India
· Delayed Price · Currency is INR 655.25
0.00 (0.00%)
At close: Jan 3, 2025
Jagsonpal Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Net Income | 243 | 224.63 | 267.21 | 188.55 | 170.58 | 78.71 | Upgrade
|
| Depreciation & Amortization | 42.28 | 16.63 | 11.75 | 15.26 | 10.86 | 11.3 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | -3.59 | -0.85 | - | -0.16 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 28.09 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | -1.48 | -11.36 | 2.51 | - | Upgrade
|
| Stock-Based Compensation | 94.76 | 133.1 | 87.65 | - | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 5.74 | 7.67 | 2.62 | 0.42 | - | - | Upgrade
|
| Other Operating Activities | -64.9 | -85.76 | -20.66 | -8.33 | -17.67 | -19.37 | Upgrade
|
| Change in Accounts Receivable | 62.02 | 91.54 | -55.56 | -29.55 | 87.89 | -7.03 | Upgrade
|
| Change in Inventory | 32.96 | 53.1 | 86.86 | -0.18 | -4 | 33.68 | Upgrade
|
| Change in Accounts Payable | -5.94 | -89.82 | -19.62 | -10.75 | 63.41 | -1.51 | Upgrade
|
| Change in Income Taxes | - | - | - | - | -92.92 | -1.91 | Upgrade
|
| Change in Other Net Operating Assets | 165.19 | 0.57 | 83.28 | -74.07 | -57.92 | 27.3 | Upgrade
|
| Operating Cash Flow | 575.11 | 351.66 | 466.55 | 69.14 | 282.22 | 118.85 | Upgrade
|
| Operating Cash Flow Growth | 15.52% | -24.63% | 574.79% | -75.50% | 137.46% | -61.53% | Upgrade
|
| Capital Expenditures | -2.53 | -2.48 | -3.18 | -10.49 | -4.69 | -18.55 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 12.96 | 5.81 | - | - | Upgrade
|
| Investment in Securities | 406.69 | -316.67 | -620.77 | -268.57 | -41.73 | -113.86 | Upgrade
|
| Other Investing Activities | 82.95 | 73.67 | 34.28 | 15.46 | 23.78 | 21.68 | Upgrade
|
| Investing Cash Flow | -398.86 | -245.48 | -576.71 | -257.79 | -22.64 | -110.73 | Upgrade
|
| Long-Term Debt Repaid | - | -6.33 | -0.44 | -67.88 | - | - | Upgrade
|
| Total Debt Repaid | -10.32 | -6.33 | -0.44 | -67.88 | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -10.32 | -6.33 | -0.44 | -67.88 | - | - | Upgrade
|
| Issuance of Common Stock | 67.81 | 56.35 | - | - | - | - | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | -36.95 | - | Upgrade
|
| Common Dividends Paid | -132.29 | -130.99 | - | -104.79 | -26.2 | -13.1 | Upgrade
|
| Other Financing Activities | -8.87 | -8.14 | -4.13 | -2.85 | -5.14 | -5.14 | Upgrade
|
| Financing Cash Flow | -83.67 | -89.11 | -4.57 | -175.52 | -68.28 | -18.24 | Upgrade
|
| Net Cash Flow | 92.58 | 17.07 | -114.73 | -364.17 | 191.3 | -10.12 | Upgrade
|
| Free Cash Flow | 572.58 | 349.18 | 463.37 | 58.65 | 277.53 | 100.31 | Upgrade
|
| Free Cash Flow Growth | 16.28% | -24.64% | 690.06% | -78.87% | 176.69% | -64.98% | Upgrade
|
| Free Cash Flow Margin | 25.24% | 16.73% | 19.58% | 2.70% | 14.77% | 6.33% | Upgrade
|
| Free Cash Flow Per Share | 21.30 | 13.15 | 17.69 | 2.24 | 10.59 | 3.83 | Upgrade
|
| Cash Interest Paid | 0.73 | - | - | 2.61 | 4.28 | 3.83 | Upgrade
|
| Cash Income Tax Paid | 75.93 | 85.13 | 72.76 | 68.73 | 31.5 | 18 | Upgrade
|
| Levered Free Cash Flow | 585.95 | 173.21 | 425.62 | 49.28 | 157.46 | 99.51 | Upgrade
|
| Unlevered Free Cash Flow | 591.26 | 178.07 | 427.36 | 50.92 | 160.13 | 101.9 | Upgrade
|
| Change in Net Working Capital | -277.86 | 104.6 | -119.36 | 103.77 | -36.54 | -62.88 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.